Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) Director David S. Tierney sold 25,000 shares of the company's stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $15.68, for a total transaction of $392,000.00. Following the sale, the director now owns 348,874 shares in the company, valued at $5,470,344.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Catalyst Pharmaceuticals Stock Up 0.6 %
Shares of Catalyst Pharmaceuticals stock opened at $15.88 on Thursday. The firm has a market capitalization of $1.87 billion, a P/E ratio of 26.03, a P/E/G ratio of 0.94 and a beta of 0.89. Catalyst Pharmaceuticals, Inc. has a 52 week low of $11.09 and a 52 week high of $18.22. The firm's 50 day moving average is $15.15 and its two-hundred day moving average is $14.38.
Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.45 by $0.04. The business had revenue of $110.57 million for the quarter, compared to analyst estimates of $105.78 million. Catalyst Pharmaceuticals had a net margin of 17.93% and a return on equity of 26.56%. As a group, research analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.81 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Catalyst Pharmaceuticals
The Best AI Stock to Own in the World Today is Trading for Just $25
From Banyan Hill Publishing | Ad
“Titan of Tech” Bets Big on Tiny AI Company
He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal…
But our research shows his latest investment could be his most successful venture yet.
See how you can invest alongside him
A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. increased its holdings in shares of Catalyst Pharmaceuticals by 3.2% in the 2nd quarter. BlackRock Inc. now owns 15,851,862 shares of the biopharmaceutical company's stock valued at $213,049,000 after acquiring an additional 491,552 shares during the period. State Street Corp increased its holdings in shares of Catalyst Pharmaceuticals by 25.3% in the 2nd quarter. State Street Corp now owns 9,453,077 shares of the biopharmaceutical company's stock valued at $127,049,000 after acquiring an additional 1,910,359 shares during the period. Vanguard Group Inc. increased its holdings in shares of Catalyst Pharmaceuticals by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 7,120,417 shares of the biopharmaceutical company's stock valued at $119,694,000 after acquiring an additional 73,930 shares during the period. Millennium Management LLC increased its holdings in shares of Catalyst Pharmaceuticals by 134.1% in the 2nd quarter. Millennium Management LLC now owns 2,723,895 shares of the biopharmaceutical company's stock valued at $19,095,000 after acquiring an additional 1,560,086 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Catalyst Pharmaceuticals by 1.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,601,797 shares of the biopharmaceutical company's stock valued at $43,738,000 after acquiring an additional 41,923 shares during the period. 79.22% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of analysts recently weighed in on the stock. TheStreet upgraded shares of Catalyst Pharmaceuticals from a "c+" rating to a "b" rating in a research note on Tuesday, March 12th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, March 21st. Citigroup assumed coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, March 14th. They set a "buy" rating and a $27.00 target price on the stock. Bank of America assumed coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, March 7th. They issued a "buy" rating and a $23.00 price target on the stock. Finally, Oppenheimer reiterated an "outperform" rating and issued a $29.00 price target on shares of Catalyst Pharmaceuticals in a research note on Wednesday, March 27th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $26.43.
Check Out Our Latest Stock Analysis on Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Company Profile
(
Get Free Report)
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
